Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Fennec Pharmaceuticals (FENC) over the last 12 years, with Q3 2025 value amounting to $43.9 million.

  • Fennec Pharmaceuticals' Total Non-Current Liabilities fell 2244.91% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 2244.91%. This contributed to the annual value of $43.9 million for FY2024, which is 4191.64% up from last year.
  • Fennec Pharmaceuticals' Total Non-Current Liabilities amounted to $43.9 million in Q3 2025, which was down 2244.91% from $43.9 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $56.8 million during Q2 2024, with a 5-year trough of $4.0 million in Q2 2022.
  • Over the past 5 years, Fennec Pharmaceuticals' median Total Non-Current Liabilities value was $25.6 million (recorded in 2023), while the average stood at $30.6 million.
  • Per our database at Business Quant, Fennec Pharmaceuticals' Total Non-Current Liabilities soared by 53624.06% in 2023 and then plummeted by 2262.5% in 2025.
  • Fennec Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $5.0 million in 2021, then surged by 399.28% to $24.9 million in 2022, then rose by 24.23% to $30.9 million in 2023, then surged by 41.92% to $43.9 million in 2024, then rose by 0.09% to $43.9 million in 2025.
  • Its Total Non-Current Liabilities stands at $43.9 million for Q3 2025, versus $43.9 million for Q2 2025 and $43.9 million for Q1 2025.